Hip Fracture Risk Up With Drug Holiday From Risedronate Versus Alendronate
THURSDAY, Jan. 13, 2022 -- Drug holidays after long-term risedronate are associated with a small increase in the risk for hip fracture compared with drug holidays after long-term alendronate, according to a study published online Jan. 11 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 13, 2022 Category: Pharmaceuticals Source Type: news
How Safe Is a Drug Holiday From Bisphosphonates for Osteoporosis? How Safe Is a Drug Holiday From Bisphosphonates for Osteoporosis?
' We found little difference in the association between risedronate versus alendronate drug holidays and hip fractures until approximately 2 years of not receiving therapy, ' researchers report.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - January 13, 2022 Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news
Actonel with Calcium (Risedronate Sodium with Calcium Carbonate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 14, 2021 Category: Drugs & Pharmacology Source Type: news
Cut Risedronate Drug Holiday to Under 2 Years in Older Patients Cut Risedronate Drug Holiday to Under 2 Years in Older Patients
Risedronate confers less hip fracture protection than alendronate during drug holidays beyond 2 years, so a 2- to 3-year drug holiday for risedronate is likely too long.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - October 6, 2021 Category: Rheumatology Tags: Diabetes & Endocrinology News Source Type: news
Bone Drugs May Have Added Benefit: Lower Pneumonia Risk
Bisphosphonates such as Fosamax and Actonel, taken for osteoporosis, were associated with a reduced risk of pneumonia. (Source: NYT Health)
Source: NYT Health - June 9, 2020 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Bisphosphonates (Drugs) Pneumonia Bone Fractures Osteoporosis Fosamax (Drug) Source Type: news
risedronate (Actonel, Atelvia)
Title: risedronate (Actonel, Atelvia)Category: MedicationsCreated: 3/12/2000 12:00:00 AMLast Editorial Review: 3/6/2019 12:00:00 AM (Source: MedicineNet Womens Health General)
Source: MedicineNet Womens Health General - March 6, 2019 Category: OBGYN Source Type: news
Risedronate Sodium Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - July 10, 2018 Category: Drugs & Pharmacology Source Type: news
European Commission Approves Prolia ® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Third Indication in Europe for Prolia for the Treatment of Patients at Increased Risk of Fractures
THOUSAND OAKS, Calif., June 8, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication for Prolia® (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. The EC approval is based on the positive results of a Phase 3 study that evaluated the safety and efficacy of Prolia compared with risedronate in patients receiving glucocorticoid treatment.1
"We are pl...
Source: Amgen News Release - June 8, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Bone Drug 'Holiday' May Raise Fracture Risk
Bisphosphonates, such as alendronate (Fosamax) and risedronate (Actonel), are the most widely prescribed osteoporosis drugs. They are designed to slow or prevent bone loss. (Source: WebMD Health)
Source: WebMD Health - May 11, 2018 Category: Consumer Health News Source Type: news
Steroid-Induced Bone Loss Better Treated With Denosumab? Steroid-Induced Bone Loss Better Treated With Denosumab?
Denosumab found to be superior to risedronate in the treatment of steroid-induced osteoporosis at 12 months, at least in terms of BMD, among patients starting steroid therapy or those who remained on it.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 10, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
$703M deal: Teva completes final divestiture of women's health products
Teva Pharmaceutical Industries Ltd. completed the $703 million sale of a portfolio of products within its global women ’s health business to CVC Capital Partners.
The portfolio of products, all marketed and sold outside the United States, includes: the fertility treatment Ovaleap, the oral contraceptives Zoely and Seasonique, and the osteoporsis drug Actonel.
The products will be sold by Theramex, previously a Teva women's health unit based in Monaco. CVC Capital Partners brought in former Allergan… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 1, 2018 Category: Pharmaceuticals Authors: John George Source Type: news
Teva closes $703m sale of global women ’s health biz to CVC Capital
Teva Pharmaceuticals (NYSE:TEVA) has finished the $703 million sale of a portfolio of products in its global women’s health business to CVC Capital Partners.
The portfolio of divested products includes fertility medicines like Ovaleap, oral contraceptives like Zoely and osteoporosis drugs like Actonel. Now that the sale is closed, the portfolio of medicines will be sold under a business branded as “Theramex,” according to Teva.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva closes $703m sale of global women’s health biz to CVC Capital appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 1, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Wall Street Beat Women's Health Teva Pharmaceuticals Source Type: news
Teriparatide Bests Risedronate for Fracture Prevention in Severe Osteoporosis
Daily subcutaneous teriparatide prevents fractures more effectively than weekly oral risedronate, finds an international, industry-conducted study in the Lancet. Over 1300 postmenopausal women with... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 13, 2017 Category: Primary Care Source Type: news
Mayo Clinic Q and A: Finding the right osteoporosis medication
DEAR MAYO CLINIC: The bisphosphonate drugs I take for osteoporosis aren?t working in my case. My doctor has suggested a few alternatives. Any thoughts on what might be best? ANSWER: Oral bisphosphonate drugs ? including alendronate (Fosamax), risedronate (Actonel and Atelvia) and ibandronate (Boniva) ? are the most commonly prescribed osteoporosis drugs. Bisphosphonates are less [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 13, 2017 Category: Databases & Libraries Source Type: news
FDA Accepts Supplemental Biologics License Application For Prolia ® (Denosumab) In Glucocorticoid-Induced Osteoporosis
Glucocorticoid-Induced Osteoporosis is the Most Common Form of Secondary Osteoporosis
THOUSAND OAKS, Calif., Oct. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia® (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP). The sBLA, which was submitted on July 28, 2017, is based on a Phase 3 study evaluating Prolia compared with risedronate in patients receiving glucocorticoid treatment. The FDA has set a Prescription Drug User Fee Act (PD...
Source: Amgen News Release - October 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
